Frontage Laboratories has signed a $50 million collaboration with China’s Yabao Pharmaceuticals Group, under which Frontage will supply pharmaceutical and regulatory development services to Yabao over five years, according to PharmaTimes.

The U.S.-based contract research, development and manufacturing group, which has a substantial presence in China, will develop sustained-release drug technologies for Yabao and provide clinical research support for its efforts to develop 20 new products for the U.S. and E.U. markets. Frontage established a subsidiary in Shanghai in 2006 and a clinical research center in Zhengzhou in 2009, and is currently completing construction of a drug development operation in Beijing.